Search

A case report published in Reactions Weekly describes a woman who developed catatonia while being treated with valbenazine for tardive dyskinesia (TD). The woman had a history of a catatonic episode but was stable on her medications at the time of TD diagnosis. After starting valbenazine, the catatonia re-emerged as an adverse reaction, and the woman experienced difficulty walking and other symptoms. Her symptoms improved when valbenazine was discontinued, but returned when she ran out of the medication. The report suggests that the woman's catatonia was likely a result of using valbenazine. [Extracted from the article]

A 37-year-old man experienced neurotoxicity in the form of catatonia while undergoing immunosuppressant therapy with tacrolimus after a kidney transplant. The man had a traumatic childhood and had previously exhibited combativeness during dialysis. He presented to the emergency department with confusion and later developed severe psychomotor retardation and verbal unresponsiveness. The man's tacrolimus levels were found to be elevated, confirming the suspicion of tacrolimus-induced neurotoxicity. Treatment with lorazepam and other medications led to a rapid improvement and complete regression of catatonia, and the tacrolimus was eventually discontinued. [Extracted from the article]

A 37-year-old man experienced neurotoxicity in the form of catatonia while undergoing immunosuppressant therapy with tacrolimus after a kidney transplant. The man had a traumatic childhood and had previously exhibited combativeness during dialysis. He presented to the emergency department with confusion and later developed severe psychomotor retardation and verbal unresponsiveness. The man's tacrolimus levels were found to be elevated, confirming the suspicion of tacrolimus-induced neurotoxicity. Treatment with lorazepam and other medications led to a rapid improvement and complete regression of catatonia, and the tacrolimus was eventually discontinued. [Extracted from the article]

An approximately 17-year-old girl developed worsening catatonia while being treated with quetiapine and olanzapine for psychosis. She had previously been diagnosed with antibody negative autoimmune encephalitis and had received corticosteroids and immune globulin, which improved her symptoms. After experiencing worsening catatonia, she was treated with lorazepam, plasmapheresis, rituximab, methylprednisolone-sodium-succinate, and electroconvulsive therapy, which significantly improved her condition. However, when she was given low-dose antipsychotic treatment with quetiapine and olanzapine, her catatonia worsened again. She received further electroconvulsive therapy and her catatonia continued to improve. [Extracted from the article]

A 38-year-old man experienced withdrawal catatonia while being treated with midazolam for sedation. He had a history of depression, type 2 diabetes mellitus, and intellectual developmental disorder, and had been taking nortriptyline, etizolam, and zolpidem for three years. After fainting and experiencing cardiopulmonary arrest, he was admitted to the ICU and diagnosed with vasospastic angina. Midazolam was discontinued on day 5 of hospitalization, leading to severe psychomotor excitement and limb movements. When midazolam was resumed, his symptoms decreased. However, on day 11, he became mute and developed symptoms of catatonia. Treatment with diazepam and lorazepam resolved all symptoms, and after 13 days of treatment, he was discharged without any psychiatric symptoms. [Extracted from the article]

A 63-year-old woman with a history of schizoaffective disorder experienced worsening catatonia while being treated with paliperidone. She later exhibited a lack of efficacy when treated with lorazepam for catatonia. The woman had a complex psychiatric history, including multiple admissions and various drug trials. She also had other medical conditions such as chronic kidney disease and hypothyroidism. After trying different medications and therapies, her condition improved when her paliperidone therapy was changed to lumateperone and her lorazepam dose was slowly weaned. She continued to receive ketamine and later received a combination of esketamine and ketamine. She is now clinically stable. [Extracted from the article]

A man in his early 20s experienced a rebound effect of catatonia aggravation during the tapering of lorazepam for the treatment of catatonia. He then exhibited a lack of efficacy when treated with olanzapine for catatonia. The man had been in custody for criminal charges and was initially admitted to a mental health observation unit. After experiencing social withdrawal and catatonic features, he was re-hospitalized and received various treatments, including electroconvulsive therapy and medications such as haloperidol, lorazepam, clonazepam, and benzatropine. His symptoms improved, and he was able to engage in conversation better. [Extracted from the article]

A 72-year-old woman developed excited catatonia while being treated with prednisone for temporal arteritis. She exhibited bizarre behaviors such as frequent verbigeration, posturing, and stereotypies. After further assessment, she was diagnosed with excited catatonia due to prednisone. Treatment with lorazepam resolved her symptoms, and she was admitted to the internal medicine service. Her prednisone was switched to tocilizumab, and benzodiazepines were tapered without a recurrence of catatonia. [Extracted from the article]

A 35-year-old man with Down syndrome, Hirschsprung's disease, and obstructive sleep apnea developed delirium and drug toxicity while being treated with methotrexate for B-cell Acute lymphoblastic leukemia. He also developed catatonia during treatment with metoclopramide for delirium, and his delirium worsened with lorazepam treatment for catatonia. The man was treated with antipsychotics initially, which helped with delirium but later precipitated catatonia. He was eventually stabilized with memantine, escitalopram, and lorazepam, and his hospital stay lasted over three months. [Extracted from the article]

A 53-year-old woman with schizoaffective disorder developed lithium toxicity in the form of catatonia while being treated with lithium. She also showed a lack of efficacy when treated with clozapine and lorazepam for the lithium toxicity. The woman received treatment with lorazepam, but it had limited effect in improving her catatonia. Electroconvulsive therapy (ECT) was consulted and pursued, resulting in mild improvements. However, she later entered a catatonic state and did not respond to clozapine and lorazepam. ECT was pursued again, and after receiving seven treatments, she was able to start eating, fulfilling her own needs, and ambulating. She was then transferred to a psychiatric hospital to stabilize her psychosis. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 50-year-old woman developed withdrawal catatonia following discontinuation of nortriptyline while being treated for major depressive disorder [route not stated]. [Extracted from the article]

A 15-year-old boy with treatment-resistant childhood-onset schizophrenia experienced malignant catatonia and hypoactive delirium due to drug interactions and oversedation. The boy was taking clozapine, fluoxetine, and ziprasidone for his condition. The interactions between these medications led to the development of hypoactive delirium and malignant catatonia. The boy's medication doses were adjusted, and he received additional treatments such as lorazepam, memantine, valproate-semisodium, and electroconvulsive therapy. His symptoms improved, and he was discharged on a modified medication regimen. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 44-year-old woman developed psychosis in the form of suicidal ideation and catatonia during treatment with hydrocortisone for adrenal insufficiency [AI; dosage and route not stated]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 34-year-old man exhibited no therapeutic response following treatment with clozapine for schizoaffective disorder. Additionally, he developed rebound catatonia following withdrawal of clozapine therapy [ I route, dosage and time to reaction onset not stated i ]. However, he developed rebound effect in the form of catatonia, due to abrupt discontinuation of clozapine therapy. [Extracted from the article]

On day 3 after the initiation of clozapine, she developed dystonia, catatonia and neuroleptic malignant syndrome. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 17-year old girl developed dystonia, catatonia and neuroleptic malignant syndrome during antipsychotic treatment with clozapine. [Extracted from the article]

Examination demonstrated mutism, stupor, negativism, waxy flexibility and posturing, compatible with malignant catatonia secondary to clozapine withdrawal indicating rebound effect. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 53-year-old woman developed rebound effect in the form of malignant catatonia upon clozapine withdrawal while being treated for schizophrenia. [Extracted from the article]

Based on the clinical presentation, he was considered to have catatonia and psychosis, which was attributed to the dexamethasone therapy. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a case series of 3 patients, a 69-year-old woman and a 74-year-old man were described, who developed psychosis and catatonia following an off-label treatment with dexamethasone for COVID-19 pneumonia [ I dosages, routes and durations of treatments to reactions onset not stated i ]. [Extracted from the article]